About

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates in the biopharmaceutical market, which involves creating drugs from biological sources. Roivant employs a unique business model that combines in-house development with strategic partnerships, allowing it to build a strong pipeline of drug candidates and utilize advanced technologies to meet medical needs. One of its key subsidiaries, Genevant, specializes in RNA therapeutics, using proprietary delivery platforms for mRNA, RNAi, and gene editing to treat specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

Simplify's Take

What believers are saying

• Acquisition of Dermavant expands Roivant's dermatology portfolio.
• Collaboration with Bayer creates Pulmovant for pulmonary hypertension treatment.
• Roche's acquisition of Telavant highlights Roivant's valuable drug pipeline.

What critics are saying

• Phase 2 failure of lupus drug brepocitinib raises concerns.
• Rumors of acquiring Immunovant may lead to financial strain.
• Dependence on strategic partnerships could impact autonomy and decision-making.

What makes Roivant Sciences unique

• Roivant Sciences builds nimble biotech companies called Vants for drug development.
• Focuses on RNA therapeutics and genetic disorders for innovative treatments.
• Unique business model combines in-house development with strategic partnerships.

Help us improve and share your feedback! Did you find this helpful?

YesNo